

# Scott L Pomeroy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8187649/publications.pdf>

Version: 2024-02-01

71  
papers

53,544  
citations

87843

38  
h-index

118793

62  
g-index

92  
all docs

92  
docs citations

92  
times ranked

85795  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15545-15550.	3.3	38,922
2	Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 2002, 415, 436-442.	13.7	2,154
3	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	3.9	1,536
4	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	3.9	863
5	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	13.7	787
6	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	13.7	765
7	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	13.7	761
8	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature, 2012, 488, 106-110.	13.7	675
9	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
10	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. Cancer Cell, 2014, 25, 393-405.	7.7	627
11	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. Journal of Clinical Oncology, 2011, 29, 1424-1430.	0.8	609
12	Medulloblastomics: the end of the beginning. Nature Reviews Cancer, 2012, 12, 818-834.	12.8	560
13	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	3.9	478
14	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	0.8	381
15	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	18.1	376
16	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathologica, 2012, 123, 615-626.	3.9	318
17	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	5.1	307
18	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	13.7	273

#	ARTICLE	IF	CITATIONS
19	SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. <i>Nature Genetics</i> , 2017, 49, 289-295.	9.4	268
20	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
21	Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. <i>Genes and Development</i> , 2004, 18, 629-640.	2.7	154
22	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2018, 34, 396-410.e8.	7.7	146
23	Pleiotropic effects of miR-183-96-182 converge to regulate cell survival, proliferation and migration in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 539-552.	3.9	145
24	Focus on central nervous system neoplasia. <i>Cancer Cell</i> , 2002, 1, 125-128.	7.7	130
25	The G protein $\alpha$ subunit $G\alpha$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	15.2	110
26	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. <i>Cancer Cell</i> , 2019, 36, 302-318.e7.	7.7	96
27	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	0.8	91
28	Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. <i>Developmental Biology</i> , 2003, 263, 50-66.	0.9	89
29	Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 994-998.	0.8	81
30	Predicting Relapse in Patients With Medulloblastoma by Integrating Evidence From Clinical and Genomic Features. <i>Journal of Clinical Oncology</i> , 2011, 29, 1415-1423.	0.8	76
31	Medulloblastoma: Molecular Classification-Based Personal Therapeutics. <i>Neurotherapeutics</i> , 2017, 14, 265-273.	2.1	66
32	Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. <i>International Journal of Cancer</i> , 2000, 89, 368-377.	2.3	65
33	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	3.9	65
34	DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with <i>In Silico</i> Analysis to Identify Novel Therapeutic Targets. <i>Clinical Cancer Research</i> , 2016, 22, 3903-3914.	3.2	54
35	Identification of PATCHED mutations in medulloblastomas by direct sequencing. <i>Human Mutation</i> , 2000, 16, 89-90.	1.1	51
36	Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. <i>Cancer</i> , 1996, 78, 864-873.	2.0	50

#	ARTICLE	IF	CITATIONS
37	Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. <i>Epilepsia</i> , 2015, 56, 1599-1604.	2.6	49
38	Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. <i>Journal of Neuro-Oncology</i> , 2018, 140, 269-279.	1.4	45
39	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	2.4	37
40	Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. <i>Neuro-Oncology</i> , 2010, 12, 1244-1256.	0.6	36
41	MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. <i>Cancer Letters</i> , 2017, 401, 20-32.	3.2	34
42	Hedgehog-Gli Pathway in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2154-2156.	0.8	30
43	Defining the Molecular Landscape of Ependymomas. <i>Cancer Cell</i> , 2015, 27, 613-615.	7.7	30
44	The evolution of medulloblastoma therapy to personalized medicine. <i>F1000Research</i> , 2017, 6, 490.	0.8	30
45	Neurotrophins in cerebellar granule cell development and medulloblastoma. <i>Journal of Neuro-Oncology</i> , 1997, 35, 347-352.	1.4	26
46	Molecular Biology of Medulloblastoma Therapy. <i>Pediatric Neurosurgery</i> , 2003, 39, 299-304.	0.4	26
47	Posterior Fossa Ependymomas: A Tale of Two Subtypes. <i>Cancer Cell</i> , 2011, 20, 133-134.	7.7	22
48	A developmental program drives aggressive embryonal brain tumors. <i>Nature Genetics</i> , 2014, 46, 2-3.	9.4	15
49	Molecular genetics of pediatric central nervous system tumors. <i>Current Oncology Reports</i> , 2006, 8, 423-429.	1.8	14
50	Crisis Standard of Care: Management of Infantile Spasms during COVID-19. <i>Annals of Neurology</i> , 2020, 88, 215-217.	2.8	13
51	Postnatal addition of satellite cells to parasympathetic neurons. , 1996, 375, 518-525.		12
52	Loss of Consciousness in the Young Child. <i>Pediatric Cardiology</i> , 2021, 42, 234-254.	0.6	8
53	Medulloblastoma biology in the post-genomic era. <i>Future Oncology</i> , 2012, 8, 1597-1604.	1.1	7
54	Introduction: Survivors of childhood cancer: The new face of developmental disabilities. <i>Developmental Disabilities Research Reviews</i> , 2008, 14, 183-184.	2.9	5

#	ARTICLE	IF	CITATIONS
55	Brain cancer genomics and epigenomics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 785-797.	1.0	5
56	Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. Annals of Neurology, 2019, 86, 332-343.	2.8	5
57	TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Letters, 2021, 504, 137-145.	3.2	5
58	Neural development and the ontogeny of central nervous system tumors. Neuron Glia Biology, 2004, 1, 127-133.	2.0	4
59	The Evolution of Child Neurology Training. Pediatric Neurology, 2017, 66, 3-4.	1.0	3
60	Epigenetics and survivorship in pediatric brain tumor patients. Journal of Neuro-Oncology, 2020, 150, 77-83.	1.4	3
61	Microarray Analysis and Proteomic Approaches to Drug Development. , 2006, , 74-88.		2
62	Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers. Journal of Neurodevelopmental Disorders, 2022, 14, 24.	1.5	2
63	Tracking the Fate of Cells in Health and Disease. New England Journal of Medicine, 2016, 375, 2494-2496.	13.9	1
64	A clinic devoted to peer victimization in special needs children. Annals of Neurology, 2016, 79, 167-168.	2.8	1
65	Neuro-oncology Training for the Child Neurology Resident. Seminars in Pediatric Neurology, 2011, 18, 120-122.	1.0	0
66	MB-27 * PATHWAY ANALYSIS OF A HUMAN NEURAL STEM CELL MODEL OF AGGRESSIVE MEDULLOBLASTOMA REVEALS CKD INHIBITION AS A POTENTIAL THERAPEUTIC MODALITY. Neuro-Oncology, 2015, 17, iii25-iii26.	0.6	0
67	MB-103DiSCoVERing INNOVATIVE THERAPIES: COMBINING GENETICALLY ACCURATE DISEASE MODELS OF MEDULLOBLASTOMA WITH ADVANCED IN SILICO ANALYSIS TO IDENTIFY NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 2016, 18, iii120.3-iii120.	0.6	0
68	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	0.6	0
69	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro-Oncology, 2019, 21, vi192-vi192.	0.6	0
70	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. Neuro-Oncology, 2019, 21, vi194-vi194.	0.6	0
71	SEQing to find hidden medulloblastoma cells. Cancer Cell, 2021, 39, 1452-1454.	7.7	0